Skip to main content
Erschienen in: Cardiovascular Intervention and Therapeutics 4/2019

14.02.2019 | Original Article

Full-metal jacket technique using second-generation drug-eluting stent: clinical and angiographic follow-up in 2 years

verfasst von: Goro Yoshioka, Nehiro Kuriyama, Nozomi Watanabe, Keiichi Ashikaga, Yoshisato Shibata, Koichi Node

Erschienen in: Cardiovascular Intervention and Therapeutics | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

The aims of this study are to evaluate the efficacy of percutaneous coronary intervention (PCI) using full-metal jacket (FMJ) with second-generation drug-eluting stents (DES). A single-center, non-randomized, retrospective study was performed from May 2005 to February 2014 at Miyazaki Medical Association Hospital, Japan. PCI using FMJ with DES was performed to treat 240 very long lesions (> 60 mm) in 240 patients. Subjects were divided into a first-generation or second-generation DES group. The primary endpoint was the incidence of major adverse cardiac events (MACE) at 2 years. MACE included all-cause death, myocardial infarction (MI), cerebrovascular event, and target vessel revascularization. The secondary endpoint was binary restenosis (> 50% stenosis) assessed by angiography at 1 year of follow-up. Second-generation DES were implanted to treat 121 lesions, and the first-generation DES were implanted to treat 119 lesions. Since 35 patients were lost to follow-up, the final analysis included 102 patients with second-generation DES and 103 with first-generation DES. At the 2-year follow-up, the incidence of MACE was significantly less in the second-generation DES group (9.8% vs. 20.4%, p = 0.03). The incidence of binary restenosis at 1 year was also significantly lower in the second-generation DES group (6.7% vs 29.1%, p < 0.01). When PCI was performed using FMJ with DES to treat very long lesion, the angiographic and clinical outcomes were better with second-generation than first-generation DES.
Literatur
1.
Zurück zum Zitat Kobayashi Y, Gregorio J, Kobayashi N, Akiyama T. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol. 1999;34(3):651–9.CrossRefPubMed Kobayashi Y, Gregorio J, Kobayashi N, Akiyama T. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol. 1999;34(3):651–9.CrossRefPubMed
2.
Zurück zum Zitat Dawkins KD, Grube E, Guagliumi G, Banning AP, TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation. 2005;112(21):3306–13.CrossRefPubMed Dawkins KD, Grube E, Guagliumi G, Banning AP, TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation. 2005;112(21):3306–13.CrossRefPubMed
3.
Zurück zum Zitat Aoki J, Ong AT, Rodriguez Granillo GA, McFadden EP. “Full metal jacket” (stented length > or = 64 mm) using drug-eluting stents for de novo coronary artery lesions. Am Heart J. 2005;150(5):994.CrossRefPubMed Aoki J, Ong AT, Rodriguez Granillo GA, McFadden EP. “Full metal jacket” (stented length > or = 64 mm) using drug-eluting stents for de novo coronary artery lesions. Am Heart J. 2005;150(5):994.CrossRefPubMed
4.
Zurück zum Zitat Lee CW, Park KH, Kim YH, Hong MK. Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions. Am J Cardiol. 2006;98(7):918–22.CrossRefPubMed Lee CW, Park KH, Kim YH, Hong MK. Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions. Am J Cardiol. 2006;98(7):918–22.CrossRefPubMed
5.
Zurück zum Zitat Andron M, Ramsdale DR, Rao A, Ramsdale KA. Clinical outcomes after percutaneous coronary intervention involving very long segments of drug-eluting stent implantation: single-center experience. J Invasive Cardiol. 2009;21(2):46–50.PubMed Andron M, Ramsdale DR, Rao A, Ramsdale KA. Clinical outcomes after percutaneous coronary intervention involving very long segments of drug-eluting stent implantation: single-center experience. J Invasive Cardiol. 2009;21(2):46–50.PubMed
6.
Zurück zum Zitat Moreno R, Fernandez C, Hernandez R, Alfonso. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954–9.CrossRefPubMed Moreno R, Fernandez C, Hernandez R, Alfonso. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954–9.CrossRefPubMed
7.
Zurück zum Zitat Mauri L, O’Malley AJ, Popma JJ, Moses JW. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol. 2005;95:1140–5.CrossRefPubMed Mauri L, O’Malley AJ, Popma JJ, Moses JW. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol. 2005;95:1140–5.CrossRefPubMed
8.
Zurück zum Zitat Latib AM, Ielasi A, Tarsia G, Mussardo A. Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. JACC Cardiovasc Interv. 2011;4:155–64.CrossRefPubMed Latib AM, Ielasi A, Tarsia G, Mussardo A. Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. JACC Cardiovasc Interv. 2011;4:155–64.CrossRefPubMed
9.
Zurück zum Zitat Tagliareni F, La Manna A, Saia F, Marzocchi A. Long-term clinical follow-up of drug-eluting stent restenosis treatment: retrospective analysis from two high volume catheterisation laboratories. EuroIntervention. 2010;5:703–8.CrossRefPubMed Tagliareni F, La Manna A, Saia F, Marzocchi A. Long-term clinical follow-up of drug-eluting stent restenosis treatment: retrospective analysis from two high volume catheterisation laboratories. EuroIntervention. 2010;5:703–8.CrossRefPubMed
10.
Zurück zum Zitat Basavarajaiah S, Naganuma T, Latib A, Hasegawa T. Extended follow-up following “full-metal jacket” percutaneous coronary interventions with drug-eluting stents. Catheter Cardiovasc Interv. 2014;84(7):1042–50.CrossRefPubMed Basavarajaiah S, Naganuma T, Latib A, Hasegawa T. Extended follow-up following “full-metal jacket” percutaneous coronary interventions with drug-eluting stents. Catheter Cardiovasc Interv. 2014;84(7):1042–50.CrossRefPubMed
11.
Zurück zum Zitat Liu J, Maehara A, Mintz GS, Weissman NJ. An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents. Am J Cardiol. 2009;103(4):501–6.CrossRefPubMed Liu J, Maehara A, Mintz GS, Weissman NJ. An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents. Am J Cardiol. 2009;103(4):501–6.CrossRefPubMed
12.
Zurück zum Zitat Claessen BE, Smits PC, Kereiakes DJ, Parise H. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent. JACC Cardiovasc Interv. 2011;4(11):1209–15.CrossRefPubMed Claessen BE, Smits PC, Kereiakes DJ, Parise H. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent. JACC Cardiovasc Interv. 2011;4(11):1209–15.CrossRefPubMed
13.
Zurück zum Zitat Yamamoto K, Sakakura K, Adachi Y, Taniguchi Y. Comparison of mid-term clinical outcomes between “complete full-metal jacket strategy” versus “incomplete full-metal jacket strategy” for diffuse right coronary artery stenosis with drug-eluting stents. J Cardiol. 2017;69(6):823–9.CrossRefPubMed Yamamoto K, Sakakura K, Adachi Y, Taniguchi Y. Comparison of mid-term clinical outcomes between “complete full-metal jacket strategy” versus “incomplete full-metal jacket strategy” for diffuse right coronary artery stenosis with drug-eluting stents. J Cardiol. 2017;69(6):823–9.CrossRefPubMed
14.
Zurück zum Zitat Yano H, Horinaka S, Ishimitsu T. Impact of everolimus-eluting stent length on long-term clinical outcomes of percutaneous coronary intervention. J Cardiol. 2018;71(5):444–51.CrossRefPubMed Yano H, Horinaka S, Ishimitsu T. Impact of everolimus-eluting stent length on long-term clinical outcomes of percutaneous coronary intervention. J Cardiol. 2018;71(5):444–51.CrossRefPubMed
15.
Zurück zum Zitat Lee PH, Lee SW, Yun SC, Bae J. Full metal jacket with drug-eluting stents for coronary chronic total occlusion. JACC Cardiovasc Interv. 2017;10(14):1405–12.CrossRefPubMed Lee PH, Lee SW, Yun SC, Bae J. Full metal jacket with drug-eluting stents for coronary chronic total occlusion. JACC Cardiovasc Interv. 2017;10(14):1405–12.CrossRefPubMed
16.
Zurück zum Zitat Lüscher TF, Steffel J, Eberli FR, Joner M. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115:1051.CrossRefPubMed Lüscher TF, Steffel J, Eberli FR, Joner M. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115:1051.CrossRefPubMed
17.
Zurück zum Zitat Räber L, Magro M, Stefanini GG, Kalesan B. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012;125:1110–21.CrossRefPubMed Räber L, Magro M, Stefanini GG, Kalesan B. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012;125:1110–21.CrossRefPubMed
18.
Zurück zum Zitat Alazzoni A, Al-Saleh A, Jolly SS. Everolimus-eluting versus paclitaxel-eluting stents in percutaneous coronary intervention: meta-analysis of randomized trials. Thrombosis. 2012;12:12636–9. Alazzoni A, Al-Saleh A, Jolly SS. Everolimus-eluting versus paclitaxel-eluting stents in percutaneous coronary intervention: meta-analysis of randomized trials. Thrombosis. 2012;12:12636–9.
19.
Zurück zum Zitat de Waha A, Dibra A, Byrne RA. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2011;4:371–7.CrossRefPubMed de Waha A, Dibra A, Byrne RA. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2011;4:371–7.CrossRefPubMed
20.
Zurück zum Zitat Jensen LO, Thayssen P, Hansen HS, Christiansen EH. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation. 2012;125:1246.CrossRefPubMed Jensen LO, Thayssen P, Hansen HS, Christiansen EH. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation. 2012;125:1246.CrossRefPubMed
21.
Zurück zum Zitat Valenti R, Migliorini A, Parodi G. Clinical and angiographic outcomes of patients treated with everolimus-eluting stents or first-generation Paclitaxel-eluting stents for unprotected left main disease. J Am Coll Cardiol. 2012;60:1217–22.CrossRefPubMed Valenti R, Migliorini A, Parodi G. Clinical and angiographic outcomes of patients treated with everolimus-eluting stents or first-generation Paclitaxel-eluting stents for unprotected left main disease. J Am Coll Cardiol. 2012;60:1217–22.CrossRefPubMed
22.
Zurück zum Zitat Garg S, Wykrzykowska J, Serruys PW. The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. EuroIntervention. 2011;6:928–35.CrossRefPubMed Garg S, Wykrzykowska J, Serruys PW. The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. EuroIntervention. 2011;6:928–35.CrossRefPubMed
23.
Zurück zum Zitat Sugihara Ryuta. Outcomes of first- versus second-generation drug-eluting. Am J Cardiol. 2017;119:852–5.CrossRefPubMed Sugihara Ryuta. Outcomes of first- versus second-generation drug-eluting. Am J Cardiol. 2017;119:852–5.CrossRefPubMed
Metadaten
Titel
Full-metal jacket technique using second-generation drug-eluting stent: clinical and angiographic follow-up in 2 years
verfasst von
Goro Yoshioka
Nehiro Kuriyama
Nozomi Watanabe
Keiichi Ashikaga
Yoshisato Shibata
Koichi Node
Publikationsdatum
14.02.2019
Verlag
Springer Japan
Erschienen in
Cardiovascular Intervention and Therapeutics / Ausgabe 4/2019
Print ISSN: 1868-4300
Elektronische ISSN: 1868-4297
DOI
https://doi.org/10.1007/s12928-019-00576-y

Weitere Artikel der Ausgabe 4/2019

Cardiovascular Intervention and Therapeutics 4/2019 Zur Ausgabe

Images in Cardiovascular Intervention

Bailout from Guideplus entrapment by coronary stent

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Frauen bekommen seltener eine intensive Statintherapie

30.04.2024 Statine Nachrichten

Frauen in den Niederlanden erhalten bei vergleichbarem kardiovaskulärem Risiko seltener eine intensive Statintherapie als Männer. Ihre LDL-Zielwerte erreichen sie aber fast ähnlich oft.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.